Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study
Not Applicable
Completed
- Conditions
- Mycobacterium Avium-Intracellulare InfectionHIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT00002037
- Locations
- 🇺🇸
New York Hosp - Cornell Med Ctr, New York, New York, United States
The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS
Not Applicable
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT00002433
- Locations
- 🇺🇸
New York Hosp - Cornell Med Ctr, New York, New York, United States
A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.
Phase 2
Completed
- Conditions
- HIV InfectionsCytopenias
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 250
- Registration Number
- NCT00002126
- Locations
- 🇺🇸
CARE Ctr / UCLA Med Ctr, Los Angeles, California, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath